Core Insights - AbbVie's Phase 2 EMPOWER trials for emraclidine did not achieve their primary endpoint of statistically significant improvement in PANSS total score compared to placebo at week 6 [1][2] - Emraclidine was well-tolerated, with an adverse event profile consistent with previous trials, indicating a safety profile comparable to Phase 1b trials [1][3] - AbbVie remains committed to analyzing the data for future steps and continues to focus on developing innovative therapies for psychiatric and neurological disorders [2][4] Clinical Trial Details - The EMPOWER clinical development program included two Phase 2 trials, EMPOWER-1 and EMPOWER-2, designed to evaluate emraclidine in patients with schizophrenia experiencing acute exacerbations [7][8] - The trials involved multiple dosing options to explore the therapeutic dose range for emraclidine [7] - A 52-week open-label extension trial, EMPOWER-3, is also part of the program, focusing on patients with stable symptoms [8] Emraclidine Overview - Emraclidine is a novel M4-selective positive allosteric modulator in development for schizophrenia and Alzheimer's disease psychosis, designed for once-daily administration without titration [6] - It selectively targets M4 muscarinic acetylcholine receptors to potentially reduce psychotic symptoms without blocking dopamine type 2 receptors, which are associated with many side effects of current antipsychotics [6] Neuroscience Focus - Neuroscience is a key area for AbbVie, which has expanded its pipeline through the acquisition of Cerevel, adding multiple clinical-stage and preclinical candidates to its existing portfolio [4][9] - AbbVie has a strong commitment to advancing treatment options for neurological and psychiatric disorders, supported by over three decades of experience in the field [9]

Core Viewpoint - High dividend yields can be misleading, but certain stocks like AbbVie, Gilead Sciences, and Pfizer present solid investment opportunities due to their strong fundamentals and consistent dividend growth [1][2]. AbbVie - AbbVie offers a 3.2% dividend yield, which is above average, and has consistently increased its dividend for years [3][4]. - The company announced a new quarterly dividend of $1.64 per share, reflecting a 5.8% increase, and has raised its quarterly dividend by 310% since its spin-off from Abbott Laboratories in 2013 [4][5]. - AbbVie generated $41.2 billion in sales over the past nine months, a 3% increase year-over-year, despite facing challenges with its top-selling drug Humira, which saw a 34% decline in sales this year [6][7]. Gilead Sciences - Gilead Sciences has a forward dividend yield of over 3.4%, significantly higher than the S&P 500 average of 1.3%, and has increased its dividends by 22.2% since late 2019 [9][10]. - The company has maintained revenue stability through its COVID-19 therapy Veklury and remains a leader in the HIV drug market with a 49% market share [10][11]. - Gilead is focusing on oncology, with over half of its 52 clinical programs dedicated to new cancer drugs or label expansions, indicating a strong pipeline for future growth [11][12]. Pfizer - Pfizer's forward dividend yield is currently at 6.1%, with a strong focus on maintaining and growing its dividend [13][14]. - The stock trades at approximately 9.2 times forward earnings, which is about half of the S&P 500 healthcare sector's forward earnings multiple [14]. - Despite potential challenges from patent expirations, Pfizer has a promising lineup of drugs and a robust pipeline with 108 programs in clinical development, including 30 in late-stage testing [15][16].

This Dividend King truly wears the crown.Certifications such as the Good Housekeeping Seal help consumers know which products are safe and perform well. Unfortunately, no Good Housekeeping Seal exists for dividend stocks.However, arguably the next best thing is for a company to belong to the elite group known as Dividend Kings. To qualify, a company must increase its dividend for at least 50 consecutive years. Most income investors will sleep better at night knowing that a stock has such an impressive divid ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Let's take a look at what these Wall Street heavyweights have to say about AbbVie (ABBV) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.AbbVie currently has an average brokerage recommendation (ABR) of ...

You can be a little greedy sometimes and find great stocks that possess solid growth prospects and also pay dividends.If you're investing in stocks that have long track records for increasing their payouts, odds are, you're buying shares of them because of their stability and the potential for dividend income. But just because a stock is an excellent dividend investment doesn't mean it can't also be a top growth stock to own. Stocks that can balance both dividends and growth can give investors the best of b ...

Everybody loves dividends, as they provide a passive income stream, limit drawdowns in other positions, and provide more than one way to profit from an investment.And when considering dividend-paying stocks, those with a history of boosting their payout are prime considerations, reflecting their commitment to increasingly rewarding shareholders.In addition, consistent dividend hikes reflect the company’s successful nature, opting to share profits with shareholders.And recently, three companies – AbbVie (ABB ...

AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Shares of this drugmaker have returned +3.5% over the past month versus the Zacks S&P 500 composite's -0.5% change. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has lost 4.8% over this period. Now the key question is: Where could the stock be headed in the near term?While media releases or rumors ab ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35565 AbbVie Inc. (Exact name of registrant as specified in its charter) Delaware 32-0375147 (State or other jurisdiction o ...

Core Insights - AbbVie has successfully navigated the challenges of losing patent protection for Humira, maintaining growth through its strong immunology portfolio and diversification efforts [1][2] - Despite a significant decline in Humira sales, AbbVie has seen substantial increases in sales from Rinvoq and Skyrizi, which are expected to continue to grow [2][3] Financial Performance - AbbVie reported Q3 sales of $14.46 billion, reflecting a 3.8% year-over-year increase, surpassing consensus estimates by 120 basis points [2][3] - The immunology segment grew by 4.8%, driven by a 13% increase in oncology sales and a 15.6% increase in neuroscience sales [2][3] - Adjusted earnings reached $3.00, up 1.7% year-over-year, exceeding forecasts by 270 basis points, indicating strong financial health [3] Guidance and Analyst Reactions - AbbVie raised its adjusted diluted EPS guidance, indicating strong operational momentum and expectations for continued growth in 2025 [4][5] - Analysts have responded positively to AbbVie's Q3 results, with all tracked revisions indicating higher price targets, suggesting a bullish outlook for the stock [5][6] Market Performance - Following the Q3 release, AbbVie’s stock price increased by 7%, reaching a new all-time high, supported by strong trading volume [7] - Technical indicators suggest a continued uptrend, with price targets ranging from $212 to $220 aligning with analyst revisions [7] Dividend and Capital Return - AbbVie offers a solid dividend yield of over 3.2%, which is significantly higher than the broad market average, indicating strong capital return potential [6]

Core Insights - AbbVie and EvolveImmune Therapeutics have announced a collaboration to develop multispecific therapeutic antibodies for cancer treatment, leveraging EvolveImmune's proprietary T-cell engager platform [1][3] - The partnership aims to address therapeutic challenges in both solid and hematologic malignancies by enhancing T-cell functionality and overcoming cancer cell resistance [2][3] Financial Terms - EvolveImmune will receive $65 million in upfront fees and equity investment from AbbVie, with potential for up to $1.4 billion in option fees and milestones, along with tiered royalty payments on net sales [3] Company Profiles - AbbVie is focused on advancing cancer treatment through innovative therapies and has a dynamic pipeline targeting various cancer types, including blood cancers and solid tumors [5][6] - EvolveImmune is developing first-in-category biotherapeutics aimed at overcoming cancer-driven immunodeficiency, with first-in-human clinical trials expected in 2025 [7]